What Happened?

Cigna’s stock price ⁢experienced a important decline on thursday, ⁣dropping over 15% by midmorning. this plunge followed the company’s proclamation that its pharmacy benefit manager, Express Scripts, will ‌move to a​ rebate-free model for many commercial health plans starting in 2027.The decision, revealed earlier this week, aims to reduce medication costs⁤ but will initially impact Cigna’s profitability.

Why Eliminate Pharmacy ‍rebates?

The ⁢move aligns Cigna with growing‍ pressure to increase openness in⁢ drug pricing and lower costs for consumers. The Trump governance previously encouraged Pharmacy Benefit Managers (PBMs) to voluntarily ​eliminate rebates. Rebates, while lowering overall plan costs, often don’t translate⁤ directly into lower prices at the pharmacy counter for patients.

The Financial Impact

While ⁤CEO David Cordani initially highlighted the potential for 30% average cost reductions⁤ on branded drugs, Chief Operating Officer Steve Miller delivered the ‍sobering financial⁣ news during the third-quarter earnings call. Eliminating rebates requires significant ‍upfront investment, impacting the company’s ⁢projected profits in the coming years. The market reacted negatively to this disclosure, driving down Cigna’s ⁣stock price.

The shift to a rebate-free model fundamentally changes⁤ how PBMs ​generate⁣ revenue. Traditionally, PBMs negotiate rebates from drug manufacturers ‍in ⁣exchange for favorable placement on formularies (lists of covered​ drugs). These⁢ rebates are a significant source of ‌income⁣ for PBMs. Without them, PBMs will need⁢ to rely more on negotiating lower net prices directly ​with manufacturers and on administrative fees.

What ‍Does ⁣This ‍Mean‌ for Consumers?

Theoretically, eliminating rebates should‍ lead to lower out-of-pocket costs for consumers, notably for branded drugs. Though, the actual impact will depend on how effectively Cigna ⁢negotiates‍ lower net prices with drug manufacturers. It’s​ also significant to note that the⁢ change​ won’t affect all plans; it applies⁢ primarily to commercial ⁢health plans starting in 2027.

Potential Benefits:

• Lower co-pays and ⁢coinsurance for branded medications.
• Increased ‍transparency in drug pricing.
• Greater predictability in medication costs.

Potential Challenges:

• Drug manufacturers may not fully pass on ⁤the rebate savings to consumers.
• The impact ⁤on generic drug prices is less clear.
• Implementation complexities could delay⁤ or diminish ⁣the ​benefits.

Industry​ Context⁢ and Analysis

The PBM‌ landscape is under increasing scrutiny. Federal ‌regulators are